

# Other Non-Reproductive Endocrine Abnormalities in the Survivors of Childhood and Adolescent Cancers: Review

## Erişkin Yaşa Gelen Çocukluk Çağı ve Adolesan Kanser Hastalarında Diğer Üreme Dışı Endokrin Anormallikler

Mehtap POLAT,<sup>a</sup>  
Yılmaz GÜZEL,<sup>b</sup>  
Özgür ÖKTEM<sup>b,c</sup>

<sup>a</sup>Anatolia IVF and Women's Health Center, Ankara

<sup>b</sup>VKV American Hospital Women's Health Center,

<sup>c</sup>Department of Obstetrics and Gynecology, Koç University Faculty of Medicine, İstanbul

Geliş Tarihi/Received: 26.06.2013  
Kabul Tarihi/Accepted: 07.01.2014

Yazışma Adresi/Correspondence:

Özgür ÖKTEM  
VKV American Hospital  
Women's Health Center,  
Koç University Faculty of Medicine,  
Department of  
Obstetrics and Gynecology, İstanbul,  
TÜRKİYE/TURKEY  
drozguroktem@gmail.com

**ABSTRACT** There are numerous treatment-related risks for long-term adverse outcomes among survivors of childhood cancer after exposure to chemotherapeutic drugs and radiotherapy. Cancer types in which risk of endocrine system abnormality is higher are central nervous system tumors, Hodgkin Lenfoma and hematological disorders with patients who underwent whole-body irradiation and high-dose, especially alkylating agents chemotherapy drugs, prior to the scheduled bone marrow transplantation. Cognitive dysfunction after cranial irradiation, poor cardiovascular outcomes, obesity, radiation-associated differences in pubertal timing, development of primary hypothyroidism, impaired skeletal growth breast cancer as a second malignant neoplasm, and osteonecrosis. Growth retardation and shortness of the target size can be seen in patients with growth hormone deficiency, central precocious puberty and primary hypothyroidism. Adrenocorticotropic hormone (ACTH) deficiency can be seen in long-term use of corticosteroids, in the presence of brain tumor, in patients undergoing radiation on the pituitary region, or depending tumor growth or compression. In this review article, up to date information about other non reproductive endocrine abnormalities in the female survivors of childhood and adolescent cancers.

**Key Words:** Endocrine system; chemotherapy, adjuvant; radiotherapy; puberty, precocious; hypothyroidism

**ÖZET** Erişkin yaşa gelen çocukluk çağı kanser hastalarında tedaviye bağlı olarak pek çok sistemik ve endokrin bozukluk izlenmektedir. Endokrin sistem anormalliği görülme riskinin en yüksek olduğu kanser türleri, santral sinir sistemi tümörleri, Hodgkin Lenfoma, hematolojik rahatsızlıklar nedeniyle kemik iliği transplantasyonu yapılması planlanan ve öncesinde tüm vücut radyoterapisi uygulanan hastalar ve yüksek doz, özellikle alkile edici ajanlarla kemoterapi uygulanan hastalardır. Özellikle kraniospinal radyasyon sonrası gelişen kognitif bozukluklar incelendiğinde, obezite, kardiyovasküler hastalık, pubertenin zamanlamasında aksaklık, tiroid fonksiyon bozuklukları, iskelet sistemi büyümesinde gerilik bunlardan bir kaçıdır. Growth Hormon eksikliği olanlarda, santral kaynaklı erken puberte gelişen hastalarda ve primer hipotiroidisi olan hastalarda da büyümede gerilik ve hedef boyda kısalık görülebilmektedir. Uzun süreli kortikosteroid kullananlarda, kranial tümör varlığında, tümörün büyümesi ve basısına bağlı olarak ya da hipotalamopitüiter bölgeye radyasyon uygulanan hastalarda adrenokortikotropik hormon (ACTH) eksikliği de görülebilmektedir. Bu derlemede, erişkin yaşa gelen çocukluk çağı ve adolesan kanser hastalarında uzun dönemde görülen üreme dışı endokrin anormallikler işlenecektir.

**Anahtar Kelimeler:** Endokrin sistem; kemoterapi, adjuvan; radyoterapi; puberte, prekoks; hipotiroidizm

Türkiye Klinikleri J Gynecol Obst 2014;24(3):179-83

There are a number of long-term morbidities that follows the treatment of childhood cancer. The Childhood Cancer Survivor Study (CCSS) provided important data on long term outcomes of survivors of pedi-

atric cancers. It is a retrospective cohort study that tracks the health status of adults who received a diagnosis of childhood cancer between 1970 and 1986 years. The study has documented an exceptionally high incidence of chronic conditions among 10,397 survivors [mean ages of 26.6 years (range, 18.0 to 48.0)] compared to siblings [mean age 29.2 years (range, 18.0 to 56.0)]. 62.3% had at least one chronic condition; 27.5% had a severe or life-threatening. The cumulative incidence of a chronic health condition reached 73.4% (95% CI, 69.0 to 77.9) 30 years after the cancer diagnosis, with a cumulative incidence of 42.4% (95% CI, 33.7 to 51.2).<sup>1</sup> Endocrine abnormalities are the most frequently reported complications in the survivors of childhood cancers.<sup>2</sup>

Table 1 summarizes common endocrine dysfunctions observed in the survivors. These complications frequently occur as late effects of cancer treatments affecting between 20 and 50% of individuals.<sup>3</sup> Patients exposed to radiotherapy and high doses of alkylating agents prior to hematopoietic stem cell transplantation (HSCT), survivors of central nervous system (CNS) tumors, and Hodgkin’s lymphoma are at particularly high risk of developing endocrine complications. Being mainly endocrine in origin these complications arise due to therapy-related damage to key endocrine organs such as the hypothalamic-pituitary axis, the thyroid gland, and the gonads; they can also affect bone mass and alter body composition and glucose homeostasis.<sup>2</sup>

**TABLE 1:** Common endocrine dysfunctions observed in the survivors.

System	Function	Complication	Cause	Dose
Hypothalamic-pituitary axis	Puberty	Precocious puberty	Cranial irradiation	• Cranial irradiation at both lower doses (18–35 Gy) and higher doses (>35 Gy) may lead to precocious puberty by disrupting inhibitory cortical influences. <sup>2</sup>
Hypothalamic-pituitary axis	Puberty	Hypogonadotropic hypogonadism	Cranial irradiation	Radiation > 50 Gy may cause hypogonadotropic hypogonadism along with deficiencies of other pituitary hormones. <sup>2</sup>
Hypothalamic-pituitary axis	Linear growth	Growth hormone deficiency	Cranial irradiation Total body irradiation Direct insult to the pituitary by tumoral extension or ablative surgery	The incidence of GH deficiency is 93% at 4 years after 44 Gy irradiation to hypothalamic-pituitary region [18]. Doses >30 Gy: effect by 5 years following exposure. Cumulative incidence 90% over 4 years. Doses 18–24 Gy: effect may not become evident for >10 years following the exposure. <sup>2</sup>
Hypothalamic-pituitary axis	Metabolism	TSH deficiency	Cranial irradiation (Radiotherapy to hypothalamic-pituitary region)	Doses >30 Gy Cumulative incidence 23% over 4 years for patients treated with doses >42 Gy [2]
Hypothalamic-pituitary axis	Metabolism	ACTH deficiency	Cranial irradiation	Doses >30 Gy: Cumulative incidence 38% over 4 years. <sup>2</sup>
Skeletal	Growth	Skeletal dysplasia	Irradiation of the spine and epiphyses	
Thyroid	Metabolism	TSH deficiency Primary hypothyroidism	Cranial radiotherapy Total body irradiation Radioactive iodine Labeled antibodies	
Adrenals	Metabolism	ACTH deficiency	Direct insult (surgery, tumoral expansion) Cranial radiotherapy Glucocorticoids (transient)	

## PUBERTY ABNORMALITIES

Of particular interest there are two important nongonadal reproductive adverse outcomes in childhood cancer survivors related to the impact of cancer therapy on hypothalamic-pituitary axis; precocious puberty and hypogonadotropic hypogonadism.

Precocious puberty is defined as the occurrence of puberty before the age of 8 years in girls. Cranial irradiation at both lower doses (18-35 Gy) and higher doses (>35 Gy) may lead to precocious puberty by disrupting inhibitory cortical influences.<sup>2</sup> However, when the dose of radiation exceeds 50 Gy hypogonadotropic hypogonadism may ensue along with a multitude of deficiencies of other pituitary hormones.<sup>4</sup> In addition to hypothalamic radiation female sex, young age and increased body mass index (BMI) are the risk factors for central precocious puberty.<sup>5</sup> Survivors of CNS tumors are more likely to have onset of menarche before age 10 years compared with their siblings (odds ratio [OR], 14.1; 95% confidence interval [95% CI], 7.0-30.9).<sup>4</sup> An age  $d^{1/4}$  year at the time of diagnosis increases the risk of early menarche along with a history of radiation to the hypothalamus-pituitary area. Sex steroid driven growth spurt is the earliest sign of puberty and may cause rapid bone age progression and further reduce the growth potential of children, most of whom carry additional risk factors for growth failure such as growth hormone deficiency and radiation-induced skeletal dysplasia. Breast development (telarche) before age 8 and the onset of other secondary sexual characteristics (e.g. pubic hair) prior to the age of 9 years are other signs of puberty that should alert clinicians for the suspicion of precocious puberty. It is important to note that children with precocious puberty who also are likely to have growth hormone deficiency may exhibit falsely reassuring 'normal' growth velocity. In these cases skeletal maturation can be assessed using the standard bone age (X-ray examination of the left wrist and hand). Advancement of the bone age more than 2 S.D. for chronological age is a consistent finding in children with precocious puberty.<sup>2</sup> Ultrasonographic (USG) examination of the repro-

ductive system is an important part of workup in girls with precocious puberty to document uterine growth on the pelvic USG, which is a sign of estrogenic stimulation, and is generally an earlier finding than bilaterally enlarged ovaries.<sup>2,6</sup>

Delayed menarche has been reported in childhood cancer survivors due to deficits of LH and FSH secretion following irradiation of the hypothalamic-pituitary region. Radiation to sellar region >30-40 Gy may cause hypogonadotropic hypogonadism albeit less often than growth hormone deficiency. Indeed, in a recent report from the CCSS, female survivors with a history of exposure to doses of radiation >30 Gy to the hypothalamic-pituitary area were less likely to experience a pregnancy.<sup>7</sup> Late menarche (defined by the onset of menses after age 16) was reported in 10.6% of the survivors.<sup>4</sup> Subtle defects in gonadotropin secretion has been described in radiation doses in the 18-24 Gy range.<sup>8</sup>

## GROWTH RESTRICTION

Impairment in linear growth and short stature in adulthood are commonly observed in childhood cancer survivors. Growth hormone deficiency, central precocious puberty and primary hypothyroidism are endocrine factors that can contribute to growth retardation. Cumulative incidence of growth hormone deficiency is about 90% in four years post-exposure to radiation to hypothalamic-pituitary area at doses >30 Gy.<sup>2</sup> The deficiency may manifest itself later on (up to ten years post-exposure) if radiation is used at lower doses. In addition, direct damage to growing epiphyseal plates, mainly vertebrae after high dose radiotherapy or total body irradiation (TBI) will cause skeletal dysplasia and impaired linear growth since epiphyseal growth plate are exquisitely sensitive to radiation.<sup>2,9</sup> Interestingly such an adverse effect on the growing plate has not been observed after high dose chemotherapy.<sup>10</sup>

## OTHER ENDOCRINE ABNORMALITIES

Obesity and disorders of glucose metabolism and thyroid gland and adrenal cortical trophic hormone

(ACTH) deficiency are other endocrine disturbances described in the survivors of childhood cancers. Increased body weight and obesity are commonly observed in the survivors of acute lymphoblastic leukemia (ALL) and brain tumors.<sup>11,12</sup> Cranial irradiation, dexamethasone therapy, female gender and young age (<4 years of age), being homozygous for a polymorphism in the leptin gene are risk factors for obesity.<sup>11,13</sup> Growth hormone deficiency, sellar tumors (by disrupting hypothalamic-pituitary functions), hyperphagia and hyperinsulinemia are other proposed factors contributing to obesity.<sup>2</sup> Overt diabetes may also develop in the survivors primarily due to insulin resistance. The main risk factors include TBI, abdominal irradiation and alkylating agents.<sup>14</sup>

Abnormalities in thyroid function are among the most common endocrine dysfunction diagnosed in the survivors of childhood cancers. Of thyroid dysfunctions primary hypothyroidism is the most common one and frequently develops following exposure of the gland to radiation. This exposure can occur in individuals treated with the following types of radiation: neck/mantle irradiation for Hodgkin's lymphoma; craniospinal irradiation for brain tumors; or TBI for cytoreduction before HSCT.<sup>2</sup> Chemotherapy alone does not seem to be associated with an increased incidence of primary hypothyroidism.<sup>15</sup> Total dose of the radiation,

duration of the follow-up, female gender, white race, and age >15 years at the time of diagnosis are risk factors for developing primary hypothyroidism.<sup>2,16</sup> In a large study from the CCSS on young adult survivors of Hodgkin's lymphoma, a cumulative incidence of hypothyroidism of 28% was observed; for those treated with doses >45 Gy, there was a 50% incidence of hypothyroidism 20 years after diagnosis.<sup>17</sup> Central hypothyroidism after TSH deficiency is another form of thyroid dysfunction reported in the survivors of childhood cancers. In a study on children receiving treatment for CNS embryonal tumors resulting in high doses of radiation to hypothalamus-pituitary area, the cumulative incidence of TSH deficiency was 23% at 4 years with a significant risk for patients with doses to the hypothalamic-pituitary area above 42 Gy.<sup>18</sup> Chemotherapy alone does not seem to be associated with central hypothyroidism.

ACTH deficiency may occur due to the prolonged use of glucocorticoids. But this form is relatively uncommon in childhood cancer survivors. Rather, tumor extension or radiation to hypothalamic-pituitary region (>30 Gy) are more common causes. In a study on children receiving treatment for CNS embryonal tumors that included high doses of radiation to the hypothalamic-pituitary area (median dose 44 Gy), the 4-year cumulative incidence of ACTH deficiency was 38%.<sup>18</sup>

## REFERENCES

- Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al.; Childhood Cancer Survivor Study. N Engl J Med 2006;355(15):1572-82.
- Chemaitilly W, Sklar CA. Endocrine complications in long-term survivors of childhood cancers. Endocr Relat Cancer 2010;17(3): R141-59.
- Diller L, Chow EJ, Gurney JG, Hudson MM, Kadin-Lottick NS, Kawashima TI, et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol 2009;27(14):2339-55.
- Armstrong GT, Whitton JA, Gajjar A, Kun LE, Chow EJ, Stovall M, et al. Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study. Cancer 2009;115(11): 2562-70.
- Oberfield SE, Soranno D, Nirenberg A, Heller G, Allen JC, David R, et al. Age at onset of puberty following high-dose central nervous system radiation therapy. Arch Pediatr Adolesc Med 1996;150(6):589-92.
- Berberoğlu M. Precocious puberty and normal variant puberty: definition, etiology, diagnosis and current management. J Clin Res Pediatr Endocrinol 2009;1(4):164-74.
- Green DM, Sklar CA, Boice JD Jr, Mulvihill JJ, Whitton JA, Stovall M, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27(14):2374-81.
- Byrne J, Fears TR, Mills JL, Zeltzer LK, Sklar C, Nicholson HS, et al. Fertility in women treated with cranial radiotherapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2004;42(7):589-97.
- Taylor RE. Cancer in children: radiotherapeutic approaches. Br Med Bull 1996;52(4):873-86.
- Gurney JG, Ness KK, Stovall M, Wolden S, Punyko JA, Neglia JP, et al. Final height and body mass index among adult survivors of childhood brain cancer: childhood cancer survivor study. J Clin Endocrinol Metab 2003; 88(10):4731-9.
- Garney EG, Liu Q, Sklar CA, Meacham LR, Mertens AC, Stovall MA, et al. Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2008;26(28):4639-45.

12. Breene RA, Williams RM, Hartle J, Gattens M, Acerini CL, Murray MJ. Auxological changes in UK survivors of childhood acute lymphoblastic leukaemia treated without cranial irradiation. *Br J Cancer* 2011;104(5):746-9.
13. Ross JA, Oeffinger KC, Davies SM, Mertens AC, Langer EK, Kiffmeyer WR, et al. Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. *J Clin Oncol* 2004;22(17):3558-62.
14. Meacham LR, Sklar CA, Li S, Liu Q, Gimpel N, Yasui Y, et al. Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study. *Arch Intern Med* 2009; 169(15):1381-8.
15. Chow EJ, Friedman DL, Stovall M, Yasui Y, Whitton JA, Robison LL, et al. Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. *Pediatr Blood Cancer* 2009; 53(3):432-7.
16. Metzger ML, Hudson MM, Somes GW, Shorr RI, Li CS, Krasin MJ, et al. White race as a risk factor for hypothyroidism after treatment for pediatric Hodgkin's lymphoma. *J Clin Oncol* 2006;24(10):1516-21.
17. Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. *J Clin Endocrinol Metab* 2000;85(9):3227-32.
18. Laughton SJ, Merchant TE, Sklar CA, Kun LE, Fouladi M, Broniscer A, et al. Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. *J Clin Oncol* 2008;26(7): 1112-8.